SGS Awarded cGMP Accreditation for New Italian Analytical Laboratory
SGS Life Science Services has been awarded cGMP accreditation for its newly added analytical laboratory, at its Livorno, Italy facility.
SGS’s first dedicated life science laboratory in Italy, the new lab will focus on analytical quality control testing, IT compliance and validation, and complements the existing service offer at the Livorno site, which provides facilities qualification, calibration and validation services, and an analytical chemistry laboratory which opened in 2013.
The 1085m² laboratory employs 25 staff, is also ISO 9001 accredited, and completes the SGS Life Science Services offering for the Italian market. cGMP accreditation enables the Livorno GMP laboratory to demonstrate, on behalf of it clients, whether or not individual batches of their raw materials, or of their regulated product, are manufactured according to the highest quality standards.
“The investment in the new laboratory and its cGMP accreditation adds significantly to our existing offer and will enable us to conveniently serve the microbiological and chemical testing needs of our clients in the important Italian market, where many multinational pharmaceutical firms and API manufacturers are located,” commented Marco Benvenuti, Business Manager, SGS Life Science Services.
Frédéric Gaussens, Vice President Global Strategy and Business Development, SGS added: “The Livorno facility further strengthens our global footprint in Europe and provides great synergies with our current method development, equipment and instrument validation and calibration services. This investment is key to our ongoing expansion programme, both strategically and geographically.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.